Observational (non-randomized) comparative studies have been adopted in the pre-market safety/effectiveness evaluation of medical devices. There has been an increased interest in utilizing this design with the growing available real-world data. However, in such studies, biases that are introduced in every stage and aspect of study need to be addressed. Otherwise, the objectivity of study design and validity of study results will be compromised. In this paper, challenges and opportunities are discussed from the regulatory perspective. Considerations and good statistical practice to mitigate the potential bias are presented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10543406.2019.1632880 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!